Sponsors (2)
The bill preserves access and lowers regulatory burdens for traditional large and premium cigar makers and buyers at the cost of limiting FDA public-health oversight and potentially increasing health risks and market unfairness.
Manufacturers of traditional large and premium cigars (including small-business owners) keep existing operations and avoid new FDA compliance costs and paperwork.
Adult consumers can continue buying traditional large and premium cigars without product changes or market disruptions from new FDA rules.
Consumers of these cigars may face higher health risks because FDA restrictions on flavors, labeling, or youth-access protections would not apply.
Public-health protections that the FDA could impose (ingredient disclosure, manufacturing standards, marketing limits) would not cover these cigars, weakening population-level tobacco control.
Exempting these cigars creates regulatory unevenness that could advantage some tobacco producers, spur classification disputes, and harm competitive fairness for other businesses.
Based on analysis of 2 sections of legislative text.
Introduced February 25, 2026 by Ashley Brooke Moody · Last progress February 25, 2026
Amends the Federal Food, Drug, and Cosmetic Act to exempt a narrowly defined category called “traditional large and premium cigars” from most federal tobacco-product requirements and forbids the FDA Secretary from issuing regulations that would apply to those cigars. The bill also provides a detailed statutory definition of which cigars qualify and makes conforming edits to another FDA tobacco provision. The main practical effect is to remove FDA regulatory authority over these defined cigars (with one limited exception preserved) which would directly affect cigar manufacturers, many small businesses in the industry, retailers, and public-health enforcement activities tied to tobacco regulation.